Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1

Sara Bringhen*, Peter M. Voorhees, Torben Plesner, Ulf-Henrik Mellqvist, Brandi Reeves, Pieter Sonneveld, Catriona Byrne, Eva Nordström, Johan Harmenberg, Jakob Obermüller, Paul G. Richardson

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time-to-next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long-term clinical benefit in patients with RRMM.

Original languageEnglish
JournalBritish Journal of Haematology
Volume193
Issue number6
Pages (from-to)1105-1109
ISSN0007-1048
DOIs
Publication statusPublished - Jun 2021

Keywords

  • melflufen
  • melphalan flufenamide
  • multiple myeloma
  • relapsed/refractory multiple myeloma

Fingerprint

Dive into the research topics of 'Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1'. Together they form a unique fingerprint.

Cite this